Key Highlights
- 9.52% is the indicated pre-market gain for Cue Biopharma, Inc. (NASDAQ:CUE) on November 18, 2026, lifting the price to USD 3.10 from a calculated prior close of USD 2.83, a calculated move of USD 0.27.
- 79.9% is the calculated decline in Cue Biopharma, Inc. (NASDAQ:CUE) on November 17, 2026, from a USD 14.10 close on November 16 to USD 2.83, in a session that followed third quarter results released after the close.
- 50.0 million is the third quarter 2026 net loss in USD at Cue Biopharma, Inc. (NASDAQ:CUE), or USD 4.74 per share, against USD 7.4 million a year earlier, with USD 29.8 million of administrative costs mostly non-cash.
- 57.9 million is the cash and equivalents balance in USD at September 30, 2026, up from USD 27.1 million at December 31, 2025, with Equity of USD 38.4 million.
What Moved Cue Biopharma, Inc. (NASDAQ:CUE) in Pre-Market Trading on November 18, 2026 (+USD 0.27, +9.52%)
The indicated pre-market price for Cue Biopharma, Inc. (NASDAQ:CUE) is USD 3.10 on November 18, 2026, a pre-market move of +9.52%. The calculated prior close, the November 17, 2026 regular-session close, is USD 2.83 (USD 3.10 divided by 1.0952), and the calculated USD move is +USD 0.27. That prior close sits 79.9% below the USD 14.10 close of November 16, 2026. Using the 10,561,814 weighted average shares of the third quarter, the indicative calculated value at USD 3.10 is about USD 32.7 million.
The Rationale: No Stated Cause for the Slide After Third Quarter Results for Cue Biopharma, Inc. (NASDAQ:CUE)
No company release dated November 18, 2026 was identified in published coverage, so the move is read as follow-through from a volatile November 17, 2026 session. The company released third quarter 2026 results at 4:48 p.m. ET on November 16, 2026, and the release did not address the price. Revenue was USD 0.1 million versus USD 2.1 million, Research and Development rose to USD 17.0 million from USD 4.8 million, and administrative expense reached USD 29.8 million from USD 4.9 million, mostly non-cash. The CUE-221 anti-IgE Phase 2 study in chronic spontaneous urticaria met its primary endpoint, with 78% of high-IgE patients on 4 mg/kg reaching complete hive resolution at week 12 versus 0% on placebo.
Valuation, Liquidity and Risks for Cue Biopharma, Inc. (NASDAQ:CUE)
The net loss was USD 50.0 million, or USD 4.74 per share on 10,561,814 weighted shares, versus USD 7.4 million and USD 2.22 per share on 3,362,311 shares a year earlier. The nine month net loss was USD 208.3 million versus USD 28.2 million, including a USD 90.0 million loss on Warrant issuance. Cash of USD 57.9 million compares with a calculated USD 5.48 per weighted average share, above the indicated USD 3.10. With a calculated value under USD 100 million, small-cap, dilution and clinical risks apply.
Where Things Stand
Cue Biopharma, Inc. (NASDAQ:CUE) is indicated up 9.52% in pre-market trading on November 18, 2026, at USD 3.10, a calculated USD 0.27 above a prior close of USD 2.83. That close was 79.9% below the USD 14.10 recorded on November 16, 2026, and the third quarter release, issued after that close, reported a net loss of USD 50.0 million and cash of USD 57.9 million but no explanation of the price move. Positive CUE-221 Phase 2 data frame the pipeline, while non-cash charges, dilution and clinical-stage uncertainty define the risk. Pre-market moves can reverse at the 9:30 a.m. ET open, and this article is not Investment advice.






Please wait processing your request...